First Modified-Live, Intranasal Vaccine Available for theReduction of Enteric Disease Caused by Bovine Coronavirus

Merck Animal Health today announced the launch of BOVILIS CORONAVIRUS, the first USDA-approved modified-live intranasal vaccine to aid in reduction of enteric disease caused by Bovine Coronavirus (BCV). Most severe during winter months, BCV is often prevalent in cow/calf beef herds and dairy calves, and is frequently diagnosed as the leading pathogen in neonatal calves. This intranasal vaccine is approved for use in calves as young as 3 days of age.

BCV is commonly transferred by animals during periods of stress, including shipping, parturition, cold weather, commingling or delivery to a backgrounding facility or feedyard. Scours and winter dysentery are often the two signs that will signal the presence of BCV. A 2012 study at the University of Wisconsin Diagnostic Laboratory tested 147 herds and found nearly half (49.4 percent) of the herds to be positive for BCV. In related research at Oklahoma State University, 37 percent of BCV cases are found in calves zero to 30-days old.

“Bovine coronavirus is far more prevalent than producers realize and, thus, the need to vaccinate is vitally important,” says Scott Nordstrom, D.V.M., Merck Animal Health. “When used as part of a complete vaccination protocol, BOVILIS CORONAVIRUS delivers protection against the enteric signs of bovine coronavirus and is a critical component in improving the overall health of cattle on an operation.”

In addition, the combination of vaccinating both dams and calves is critical to best management practices for scours protection. “Consistent vaccination of dams with GUARDIAN® and calves with BOVILIS CORONAVIRUS can greatly reduce the impact of BCV in the herd and helps ensure the maternal antibodies are passed through to the calves,” says Dr. Nordstrom.

BOVILIS® CORONAVIRUS

Product research results showed the occurrence of scours in BOVILIS CORONAVIRUS-vaccinated calves was reduced by one-third and average duration of clinical signs was reduced to 3.40 days; versus an average of nearly seven (6.82) days in the control group. In addition, the severity of the symptoms was significantly less in the vaccinated calves compared to the control group. Results of the safety trials demonstrated the vaccine is safe to use in calves as young as 1 day of age.BOVILIS CORONAVIRUS is available in 25-dose trays, 10-dose and 50-dose bottles. GUARDIAN is available in 10-dose and 50-dose bottles.